GLUE Stock Price, Monte Rosa Therapeutics, . Quote, Chart

Market Summary

USD5.60-0.34

Market Closed

-5.72%

GLUE Stock Price

View Fullscreen

GLUE RSI Chart

GLUE Valuation

Market Cap

280.9M

Price/Earnings (Trailing)

-2.08

EV/EBITDA

-1.19

Price/Free Cashflow

-4.47

MarketCap/EBT

-2.08

GLUE Price/Earnings (Trailing)

GLUE Profitability

Return on Equity

-75.51%

Return on Assets

-44.56%

Free Cashflow Yield

-22.37%

GLUE Fundamentals

GLUE Earnings

Earnings (TTM)

-135.4M

Earnings Growth (Yr)

-8.02%

Earnings Growth (Qtr)

4.68%

Breaking Down GLUE Revenue

Last 7 days

2.8%

Last 30 days

-17.6%

Last 90 days

18.6%

Trailing 12 Months

14.1%

How does GLUE drawdown profile look like?

GLUE Financial Health

Current Ratio

5.07

GLUE Investor Care

Shares Dilution (1Y)

3.48%

Tracking the Latest Insider Buys and Sells of Monte Rosa Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 28, 2021	versant venture capital vi, l.p.	acquired	-	-	6,515,870	-
Jun 28, 2021	cormorant asset management, lp	acquired	-	-	2,602,200	-
Jun 28, 2021	behbahani ali	acquired	-	-	6,642,300	-
Jun 28, 2021	behbahani ali	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	landsman liza	acquired	-	-	6,642,300	-
Jun 28, 2021	landsman liza	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	makhzoumi mohamad	acquired	-	-	6,642,300	-
Jun 28, 2021	makhzoumi mohamad	bought	19,950,000	19.00	1,050,000	-
Jun 28, 2021	versant venture capital vi, l.p.	acquired	-	-	1,940,040	-
Jun 28, 2021	cormorant asset management, lp	bought	11,400,000	19.00	600,000	-

Which funds bought or sold GLUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	unchanged	-	13,379	80,874	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	42.00	42.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-56,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.46	94,919	662,834	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-63.59	-8,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	15,615	102,587	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	100	198,050	329,848	0.01%
Apr 12, 2024	Sarasin & Partners LLP	unchanged	-	91,113	458,821	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	367	367	-%

Are Funds Buying or Selling GLUE?

Are funds buying GLUE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GLUE

No. of Funds

Unveiling Monte Rosa Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	price t rowe associates inc /md/	10.2%	5,096,787	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.9%	4,941,707	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.1%	4,535,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	blackrock inc.	4.7%	2,371,980	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.8%	4,916,095	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Nov 09, 2023	versant venture capital vi, l.p.	13.7%	6,799,115	SC 13D/A
Feb 14, 2023	avoro capital advisors llc	8.9%	4,325,000	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	7.6%	3,683,430	SC 13G/A

Recent SEC filings of Monte Rosa Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 01, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 10, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report

Peers (Alternatives to Monte Rosa Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Monte Rosa Therapeutics, Inc. News

Latest updates

Monte Rosa Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	20.5%	304	252	279	309	342	358	365	346	366	384	369	49.00
Current Assets	29.1%	236	183	208	241	276	295	297	320	349	371	358	44.00
Cash Equivalents	116.9%	128	59.00	47.00	52.00	55.00	112	104	138	351	367	357	43.00
Net PPE	-3.4%	34.00	35.00	35.00	33.00	27.00	19.00	15.00	13.00	12.00	12.00	9.00	5.00
Liabilities	84.2%	125	68.00	65.00	65.00	71.00	67.00	63.00	20.00	19.00	15.00	12.00	30.00
Current Liabilities	106.1%	47.00	23.00	19.00	21.00	26.00	22.00	15.00	12.00	17.00	13.00	11.00	29.00
Shareholder's Equity	-2.9%	179	185	214	244	271	291	302	326	348	369	357	49.00
Retained Earnings	-10.0%	-365	-332	-297	-262	-230	-199	-172	-145	-122	-98.60	-78.76	-48.08
Additional Paid-In Capital	5.6%	548	519	513	508	504	493	477	474	472	470	437	0.00
Shares Outstanding	0.1%	50.00	50.00	50.00	49.00	49.00	47.00	47.00	47.00	47.00	18.00	5.00	2.00
Float	-	-	-	234	-	-	-	303	-	-	-	655	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	219.9%	29,634	-24,706	-25,324	-23,406	-23,961	-20,600	-20,501	-27,404	-14,172	-17,794	-13,582	-13,815	-	-	-
Share Based Compensation	-8.8%	4,074	4,468	4,153	3,974	3,326	3,214	2,873	2,251	1,856	2,073	1,019	252	-	-	-
Cashflow From Investing	-59.9%	14,297	35,628	18,550	20,326	-53,939	29,489	-14,249	-180,520	-3,047	-1,688	-2,701	-2,217	-	-	-
Cashflow From Financing	2186.4%	25,173	1,101	1,200	18.00	20,434	-217	96.00	153	-135	29,456	205,472	142,769	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GLUE Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 111,272	$ 85,061
General and administrative	32,039	27,323
Total operating expenses	143,311	112,384
Loss from operations	(143,311)	(112,384)
Other income (expense):
Interest income	9,334	3,764
Foreign currency exchange gain (loss), net	(930)	10
Gain on disposal of fixed assets	24	109
Loss on sale of marketable securities	(131)	0
Total other income	8,297	3,883
Net loss before income taxes	(135,014)	(108,501)
Provision for income taxes	(338)	0
Net loss	$ (135,352)	$ (108,501)
Net loss per share attributable to common stockholders - basic	$ (2.63)	$ (2.3)
Net loss per share attributable to common stockholders - diluted	$ (2.63)	$ (2.3)
Weighted-average number of shares outstanding used in computing net loss per common share - basic	51,396,961	47,227,370
Weighted-average number of shares outstanding used in computing net loss per common share - diluted	51,396,961	47,227,370
Comprehensive loss:
Net Income (Loss)	$ (135,352)	$ (108,501)
Other comprehensive gain (loss):
Provision for pension benefit obligation	(1,369)	718
Unrealized gain (loss) on available-for-sale securities	397	(449)
Comprehensive loss	$ (136,324)	$ (108,232)

GLUE Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 128,101	$ 54,912
Marketable securities	104,312	207,914
Other receivables	505	7,656
Prepaid expenses and other current assets	3,294	4,444
Current restricted cash	0	960
Total current assets	236,212	275,886
Property and equipment, net	33,803	27,075
Operating lease right-of-use assets	28,808	34,832
Restricted cash, net of current	4,580	4,318
Other long-term assets	352	278
Total assets	303,755	342,389
Current liabilities:
Accounts payable	11,152	7,862
Accrued expenses and other current liabilities	14,600	14,580
Current deferred revenue	17,678	0
Current portion of operating lease liability	3,162	3,127
Total current liabilities	46,592	25,569
Deferred revenue, net of current	32,323	0
Defined benefit plan liability	2,713	1,533
Operating lease liability	42,877	43,874
Total liabilities	124,505	70,976
Commitments and contingencies
Stockholders equity (deficit)
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023; and 500,000,000 shares authorized, 49,445,802 shares issued and 49,323,531 shares outstanding as of December 31, 2022	5	5
Additional paid-in capital	547,857	503,696
Accumulated other comprehensive loss	(2,724)	(1,752)
Accumulated deficit	(365,888)	(230,536)
Total stockholders' equity	179,250	271,413
Total liabilities and stockholders' equity	$ 303,755	$ 342,389

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

CEO	Dr. Markus Warmuth M.D.
WEBSITE	monterosatx.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Monte Rosa Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Monte Rosa Therapeutics, Inc.? What does GLUE stand for in stocks?

GLUE is the stock ticker symbol of Monte Rosa Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Monte Rosa Therapeutics, Inc. (GLUE)?

As of Thu May 02 2024, market cap of Monte Rosa Therapeutics, Inc. is 280.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLUE stock?

You can check GLUE's fair value in chart for subscribers.

What is the fair value of GLUE stock?

You can check GLUE's fair value in chart for subscribers. The fair value of Monte Rosa Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Monte Rosa Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Monte Rosa Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GLUE is over valued or under valued. Whether Monte Rosa Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Monte Rosa Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLUE.